These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8772621)

  • 41. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.
    Bloch KV; Salles GF; Muxfeldt ES; Da Rocha Nogueira A
    J Hypertens; 2003 Nov; 21(11):2159-65. PubMed ID: 14597860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implications of 4S evidence on baseline lipid levels.
    Durrington PN
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
    [No Abstract]   [Full Text] [Related]  

  • 43. [Lipid status and basal steroid hormone level following 16 weeks of lovastatin therapy in primary hypercholesterolemia].
    Stürmer W; Kromer EP; Riegger AJ; Kochsiek K
    Klin Wochenschr; 1991 May; 69(7):307-12. PubMed ID: 1648647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
    Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
    JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
    Mitropoulos KA; Armitage JM; Collins R; Meade TW; Reeves BE; Wallendszus KR; Wilson SS; Lawson A; Peto R
    Eur Heart J; 1997 Feb; 18(2):235-41. PubMed ID: 9043839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
    Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G
    Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
    Tuomilehto J
    Diabetes Res Clin Pract; 2003 Jul; 61 Suppl 1():S27-34. PubMed ID: 12880692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).
    Pyŏrälä K; Pedersen TR; Kjekshus J; Faergeman O; Olsson AG; Thorgeirsson G
    Diabetes Care; 1997 Apr; 20(4):614-20. PubMed ID: 9096989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.
    McNulty SJ; Ur E; Williams G;
    Diabetes Care; 2003 Jan; 26(1):125-31. PubMed ID: 12502668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia.
    Reyna-Villasmil N; Bermúdez-Pirela V; Mengual-Moreno E; Arias N; Cano-Ponce C; Leal-Gonzalez E; Souki A; Inglett GE; Israili ZH; Hernández-Hernández R; Valasco M; Arraiz N
    Am J Ther; 2007; 14(2):203-12. PubMed ID: 17414591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
    Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
    Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
    Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M
    Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology).
    Esselstyn CB
    Am J Cardiol; 1999 Aug; 84(3):339-41, A8. PubMed ID: 10496449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypolipidemic effect of the Chinese polyherbal Huanglian Jiedu decoction in type 2 diabetic rats and its possible mechanism.
    Zhang XJ; Deng YX; Shi QZ; He MY; Chen B; Qiu XM
    Phytomedicine; 2014 Apr; 21(5):615-23. PubMed ID: 24368167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.
    Lalor BC; Bhatnagar D; Winocour PH; Ishola M; Arrol S; Brading M; Durrington PN
    Diabet Med; 1990; 7(3):242-5. PubMed ID: 2158410
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin.
    Gullestad L; Nordal KP; Forfang K; Ihlen H; Høstmark A; Berg KJ; Cheng H; Schwartz MS; Geiran O; Simonsen S
    J Intern Med; 1997 Dec; 242(6):483-90. PubMed ID: 9437409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.